After an inspection by the Medicines and Healthcare Product Regulatory Agency (MHRA), Sharp will now offer clinical trial and commercial services at its $12.67m (£9.7m) Clinical Services Center of Excellence in Rhymney, Wales.
The center will enable Sharp to offer integrated services such as serialization and interactive response technology (IRT) solutions for clinical trial management. The new facility also triples its clinical service capacity.
IRT solutions offered at the center are made available after Sharp recently invested $650,000 in the technology in an aim to ensure proper supply allocations for its clinical trials. At the time, Sharp stated that the addition of IRT mitigates the potential cost of overproduction in clinical trials.
Frank Lis, president of Sharp Clinical Services, said in a statement that the facility will be able to provide full-service support to meet the growing global demand for Phase III clinical trials and commercial services.
Sharp has additionally invested in a solar panel system to generate approximately 20% of its total annual electricity requirements at the site. This system will reduce the company’s carbon footprint and improve environmental performance.
Not long before the completion and approval of the Welsh site, Sharp completed an expansion of its clinical facility in Bethlehem, PA in the US to refit the facility and relocate services from the company’s previous Phoenixville site.
The clinical services company received the MHRA approval just as it celebrated its 30th year in clinical operations in the UK.